Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?

Core Viewpoint - Zevra Therapeutics (ZVRA) has seen a 16.8% increase in share price over the past four weeks, closing at $10.99, with analysts suggesting a potential upside of 117.1% based on a mean price target of $23.86 [1][4]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates with a standard deviation of $3.39, indicating a range of potential outcomes; the lowest estimate is $19.00 (72.9% increase), while the highest is $29.00 (163.9% increase) [2][9]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction, although it does not guarantee that the stock will reach the average target [9][10]. Earnings Estimates and Market Sentiment - Analysts are optimistic about ZVRA's earnings prospects, as indicated by a significant increase in earnings estimate revisions, with a 337.1% rise in the Zacks Consensus Estimate for the current year [11][12]. - ZVRA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential for near-term upside [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the positive direction indicated by earnings estimate revisions appears to be a valid guide for potential stock price movements [14].